007370 — Jin Yang Pharmaceutical Co Balance Sheet
0.000.00%
- KR₩63bn
- KR₩135bn
- KR₩113bn
Annual balance sheet for Jin Yang Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 5,325 | 14,875 | 10,494 | 8,595 | 2,013 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 15,441 | 17,012 | 20,248 | 21,788 | 26,498 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 28,712 | 41,005 | 46,329 | 48,029 | 43,355 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 27,761 | 39,363 | 43,794 | 44,136 | 43,494 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 71,591 | 98,502 | 114,444 | 119,907 | 227,574 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18,507 | 27,143 | 30,938 | 24,511 | 19,794 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 23,320 | 33,184 | 36,869 | 30,323 | 107,696 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 48,270 | 65,318 | 77,575 | 89,583 | 119,878 |
| Total Liabilities & Shareholders' Equity | 71,591 | 98,502 | 114,444 | 119,907 | 227,574 |
| Total Common Shares Outstanding |